Aquestive Therapeutics Files 8-K
Ticker: AQST · Form: 8-K · Filed: Oct 8, 2025 · CIK: 1398733
| Field | Detail |
|---|---|
| Company | Aquestive Therapeutics, Inc. (AQST) |
| Form Type | 8-K |
| Filed Date | Oct 8, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 8-k, disclosure
Related Tickers: AQST
TL;DR
AQST filed an 8-K on 10/8/25, likely containing event/financial updates.
AI Summary
Aquestive Therapeutics, Inc. filed an 8-K on October 8, 2025, reporting "Other Events" and "Financial Statements and Exhibits." The filing does not detail specific events or financial figures but serves as a notification of these items to the SEC. The company, formerly known as MonoSol Rx, Inc., is incorporated in Delaware and headquartered in Warren, NJ.
Why It Matters
This 8-K filing indicates that Aquestive Therapeutics has submitted required disclosures to the SEC, which may contain updates on company events or financial performance.
Risk Assessment
Risk Level: low — The filing is a standard procedural disclosure and does not contain specific negative or positive news that would immediately impact risk.
Key Players & Entities
- Aquestive Therapeutics, Inc. (company) — Registrant
- MonoSol Rx, Inc. (company) — Former company name
- October 8, 2025 (date) — Date of report
- 30 Technology Drive Warren, NJ 07059 (location) — Principal Executive Offices
FAQ
What specific 'Other Events' are being reported by Aquestive Therapeutics, Inc. in this 8-K filing?
The provided text of the 8-K filing does not specify the details of the 'Other Events' beyond listing it as an item information category.
What financial statements or exhibits are included with this 8-K filing?
The filing lists 'Financial Statements and Exhibits' as an item information category, but the specific contents are not detailed in the provided text.
When was Aquestive Therapeutics, Inc. formerly known as MonoSol Rx, Inc.?
The date of the name change from MonoSol Rx, Inc. to Aquestive Therapeutics, Inc. was May 7, 2007.
What is the principal executive office address and phone number for Aquestive Therapeutics, Inc.?
The principal executive offices are located at 30 Technology Drive, Warren, NJ 07059, and the telephone number is (908) 941-1900.
Under which section of the Securities Exchange Act of 1934 is this 8-K filing being made?
This 8-K filing is being made pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Filing Stats: 442 words · 2 min read · ~1 pages · Grade level 10.1 · Accepted 2025-10-08 07:23:31
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share AQST Nasdaq Global Market I
Filing Documents
- aqst-20251008.htm (8-K) — 26KB
- iprelease10-6x25.htm (EX-99.1) — 13KB
- iprelease10-6x25001.jpg (GRAPHIC) — 229KB
- iprelease10-6x25002.jpg (GRAPHIC) — 259KB
- iprelease10-6x25003.jpg (GRAPHIC) — 299KB
- iprelease10-6x25004.jpg (GRAPHIC) — 154KB
- 0001398733-25-000022.txt ( ) — 1454KB
- aqst-20251008.xsd (EX-101.SCH) — 2KB
- aqst-20251008_lab.xml (EX-101.LAB) — 21KB
- aqst-20251008_pre.xml (EX-101.PRE) — 12KB
- aqst-20251008_htm.xml (XML) — 3KB
01
Item 8.01 Other Events. On October 8, 2025, Aquestive Therapeutics, Inc. (the "Company") issued a press release announcing the United States Patent and Trademark Office has issued two additional U.S. patents related to Anaphylm, the Company's novel epinephrine prodrug sublingual film. A copy of the Company's press release is attached as Exhibit 99.1 to this Current Report and incorporated in this Item 8.01 by reference.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Aquestive Therapeutics, Inc. Press Release, dated October 8, 2025 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: October 8, 2025 Aquestive Therapeutics, Inc. By: /s/ A. Ernest Toth, Jr Name: A. Ernest Toth, Jr. Title: Chief Financial Officer